Literature DB >> 11322796

A MEK inhibitor, PD98059 enhances IL-1-induced NF-kappaB activation by the enhanced and sustained degradation of IkappaBalpha.

M Funakoshi1, K Tago, Y Sonoda, S Tominaga , T Kasahara.   

Abstract

Interleukin-1 (IL-1) mediates numerous host responses through rapid activation of nuclear factor-kappaB (NF-kappaB), but signal pathways leading to the NF-kappaB activation appear to be complicated and multiplex. We propose a novel regulatory system for NF-kappaB activation by the extracellular signal-related kinase (ERK) pathway. In a human glioblastoma cell line, T98G, IL-1-induced NF-kappaB activation was significantly augmented by the pretreatment of a specific MEK inhibitor, PD98059. In contrast, ectopic expression of a constitutive activated form of Raf (v-Raf) reduced IL-1-induced NF-kappaB activation, and this inhibition was completely reversed by PD98059. Interestingly, PD98059 sustained IL-1-induced NF-kappaB DNA binding activity by an electrophoretic mobility shift assay and also IkappaBalpha degradation, presumably by augmenting and sustaining the proteasome activation. Concomitantly, two NF-kappaB dependent genes, A20 and IkappaBalpha expression were prolonged with PD98059. These data suggested that MEK-ERK pathway exerts a regulatory effect on NF-kappaB activation, providing a novel insight on the role of MEK-ERK pathway. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11322796     DOI: 10.1006/bbrc.2001.4759

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  6 in total

Review 1.  Mechanisms of drug combinations: interaction and network perspectives.

Authors:  Jia Jia; Feng Zhu; Xiaohua Ma; Zhiwei Cao; Zhiwei W Cao; Yixue Li; Yixue X Li; Yu Zong Chen
Journal:  Nat Rev Drug Discov       Date:  2009-02       Impact factor: 84.694

2.  Simultaneous suppression of the MAP kinase and NF-κB pathways provides a robust therapeutic potential for thyroid cancer.

Authors:  Koji Tsumagari; Zakaria Y Abd Elmageed; Andrew B Sholl; Paul Friedlander; Mohamed Abdraboh; Mingzhao Xing; A Hamid Boulares; Emad Kandil
Journal:  Cancer Lett       Date:  2015-07-21       Impact factor: 8.679

3.  Ubiquitin-editing enzyme A20 promotes tolerance to lipopolysaccharide in enterocytes.

Authors:  Jin Wang; Yannan Ouyang; Yigit Guner; Henri R Ford; Anatoly V Grishin
Journal:  J Immunol       Date:  2009-07-01       Impact factor: 5.422

4.  Tumour necrosis factor-alpha-mediated human polymeric immunoglobulin receptor expression is regulated by both mitogen-activated protein kinase and phosphatidylinositol-3-kinase in HT-29 cell line.

Authors:  N Takenouchi-Ohkubo; I Moro; S Mukae; Y Kaneko; K Komiyama
Journal:  Immunology       Date:  2007-10-25       Impact factor: 7.397

5.  Inhibition of c-Jun NH2-terminal kinase or extracellular signal-regulated kinase improves lung injury.

Authors:  Hui Su Lee; Hee Jae Kim; Chang Sook Moon; Young Hae Chong; Jihee Lee Kang
Journal:  Respir Res       Date:  2004-11-27

6.  Grainyhead-like 2 (GRHL2) knockout abolishes oral cancer development through reciprocal regulation of the MAP kinase and TGF-β signaling pathways.

Authors:  Wei Chen; Kyung L Kang; Abdullah Alshaikh; Saaket Varma; Yi-Ling Lin; Ki-Hyuk Shin; Reuben Kim; Cun-Yu Wang; No-Hee Park; Katharina Walentin; Kai M Schmidt-Ott; Mo K Kang
Journal:  Oncogenesis       Date:  2018-05-08       Impact factor: 7.485

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.